Introgen Therapeutics, Inc. Receives Broad U.S. Patent for Improved Storage-Stable Formulations of its Adenoviral-Based Pharmaceuticals

AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that a patent covering adenovirus compositions including its product ADVEXIN has been awarded by the by the U.S. Patent and Trademark Office. Patent number 7,235,391, titled Formulations of Adenovirus for Gene Therapy, relates to improved pharmaceutical formulations for the long-term storage of adenoviruses.

MORE ON THIS TOPIC